Compound ID | 2020
Class: Polymyxin
| Agent Type: | Natural product; Direct acting; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Membrane-active agent. Disrupts the outer membrane by direct interaction with the lipid A component of the LPS and disrupts the physical integrity of the phospholipid bilayer of the inner membrane. |
| Target Pathogen: | Active against Gram-negative bacteria including Acinetobacter and Pseudomonas |
| Description: | Natural product produced by Paenibacillus polymyxa. Polymyxin B is composed of polymyxins B1, B1-I, B2, B3, and B6. Used for systemic and topical treatment of Gram-negative infections. |
| Year first mentioned: | 1947 |
| Highest development stage: | Approved by FDA |
| Development status: | Approved |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/5702105 |
| Guide to Pharmacology: | polymyxin B |
| Citations: |
|